Erlotinib 150mg/day, oral daily Bevacizumab 15mg/kg, intravenous q3w
Sponsors
Department of Respiratory Medicine, Kumamoto University Hospital
Conditions
Non-Small-Cell Lung Cancer
Phase 2
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.
Active, not recruitingJPRN-UMIN000012515
Start: 2013-12-01Target: 16Updated: 2026-06-29
A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations.
Active, not recruitingJPRN-UMIN000012514
Start: 2014-01-01Target: 16Updated: 2026-06-29